ObesityPhase 1NCT07808073
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1 study testing LY4329090 in people with Obesity and Overweight, run by Eli Lilly and Company at 3 sites in 2 countries.
Trial summary
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity, Overweight
- What is being tested?
- LY4329090
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 184 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 22 Sep 2026to Sep 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent.
- Are overtly healthy with no comorbidities related to body mass index (BMI).
- Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m², inclusive.
- Have had a self-reported stable weight for 3 months prior to screening.
Who cannot join
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders.
- Have a history of chronic medical conditions involving the heart, liver, or kidneys.
- Have either
- ongoing asymptomatic bradycardia defined as less than 50 beats per minute at screening visit
- electrocardiogram (ECG) findings at screening visit of second-degree atrioventricular block or higher, or
- history of symptomatic bradycardia with uncorrected etiology, including diagnosis of sick sinus syndrome.
Show all 19Show fewer
- Have an abnormal blood pressure and/or pulse rate at screening.
- Have an obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
- Have any of the following:
- a diagnosis of hypocalcemia or hypercalcemia, or
- confirmed abnormal laboratory values for calcium and serum phosphorus.
- Have a known, clinically significant gastric emptying abnormality, have undergone weight loss surgery, or have had endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.
- Have been diagnosed with type 1 or type 2 diabetes mellitus or have glycated hemoglobin A1c (HbA1c) greater than or equal to (≥) 6.5 percent (%) or 48 millimoles per mole (mmol/mol) at screening.
- Have a history or presence of psychiatric disorders, within the last 2 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
- Have taken any glucose-lowering medications, including insulin, in the past 3 months before screening.
- Have received any drugs from the incretins class within 90 days prior to screening.
- Have been treated within 3 months prior to screening or plan to be treated with prescription medications that promote weight loss.
- Intend to use any weight loss medications during study participation.
- Prior (within 6 months) or planned (during the study) device-based treatment use for obesity.
Trial locations and contacts
3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
3 sites in 2 countries
United States2 sites, 2 recruiting
- Recruiting
Fortrea Clinical Research Unit
Dallas, Texas, 75247
866-429-3700
Gene Voskuhl
- Recruiting
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117
386-366-6417
Chiamaka Iheme
Singapore1 site, 1 recruiting
- Not yet recruiting
Lilly Centre for Clinical Pharmacology
Singapore, 138623
Jeffer Hann Wei Pang
About this study
Official title: A Phase 1, Participant- and Investigator-Blind, Single-Ascending and Multiple- Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4329090 in Participants With Obesity or Overweight
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participants will be in one of 2 parts. For each participant in Part A, the study will last about 10 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 5 nights along with 5 outpatient visits to the CRU. For each participant in Part B, the study will last about 21 weeks and will include 4 stays totaling 11 nights along with 14 outpatient visits to the CRU.
- Conditions
- Obesity, Overweight
- Being tested
- LY4329090, Placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LY4329090Drug
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| LY4329090 Part A | Experimental | Participants will receive LY4329090 administered subcutaneously (SC) Receives: Drug: LY4329090 |
| Placebo Part A | Experimental | Participants will receive placebo administered SC Receives: Drug: Placebo |
| LY4329090 Part B | Experimental | Participants will receive LY4329090 administered SC Receives: Drug: LY4329090 |
| Placebo Part B | Placebo comparator | Participants will receive placebo administered SC Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured: End of Study (Week 28)
Secondary outcomes (4)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4329090
Measured: Baseline through Week 28
PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4329090
Measured: Baseline through Week 28
PK: Area Under the Concentration Versus Time Curve (AUC) of LY4329090
Measured: Baseline through Week 28
Pharmacodynamics (PD): Body Weight Change from Baseline
Measured: Baseline through Week 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2026
- Study start22 Sep 2026
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 184 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07808073
- Sponsor's protocol ID
- 27900
- Other IDs
- J7O-MC-YVAA
- Status last verified
- Oct 2026
- First submitted
- 3 Sep 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Participant- and Investigator-Blind, Single-Ascending and Multiple- Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4329090 in Participants With Obesity or Overweight
- ClinicalTrials.gov ID
- NCT07808073
- Acronym / sponsor ID
- 27900
- Conditions
- Obesity, Overweight
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 184 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 22 Sep 2026 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 8 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participants will be in one of 2 parts. For each participant in Part A, the study will last about 10 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 5 nights along with 5 outpatient visits to the CRU. For each participant in Part B, the study will last about 21 weeks and will include 4 stays totaling 11 nights along with 14 outpatient visits to the CRU.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| LY4329090 Part A | Experimental | Drug: LY4329090Participants will receive LY4329090 administered subcutaneously (SC) |
| Placebo Part A | Experimental | Drug: PlaceboParticipants will receive placebo administered SC |
| LY4329090 Part B | Experimental | Drug: LY4329090Participants will receive LY4329090 administered SC |
| Placebo Part B | Placebo comparator | Drug: PlaceboParticipants will receive placebo administered SC |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent.
- Are overtly healthy with no comorbidities related to body mass index (BMI).
- Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m², inclusive.
- Have had a self-reported stable weight for 3 months prior to screening.
Key exclusion criteria (19 listed)
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders.
- Have a history of chronic medical conditions involving the heart, liver, or kidneys.
- Have either
- Have an abnormal blood pressure and/or pulse rate at screening.
- Have an obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LY4329090Administered SC | Drug | LY4329090 Part A, LY4329090 Part B |
| PlaceboAdministered SC | Drug | Placebo Part A, Placebo Part B |
Primary outcome
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: End of Study (Week 28)
4 secondary outcomes
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4329090
Time frame: Baseline through Week 28
PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4329090
Time frame: Baseline through Week 28
PK: Area Under the Concentration Versus Time Curve (AUC) of LY4329090
Time frame: Baseline through Week 28
Pharmacodynamics (PD): Body Weight Change from Baseline
Time frame: Baseline through Week 28
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing LY4329090 in people with Obesity and Overweight, run by Eli Lilly and Company at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States, Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (time frame: End of Study (Week 28)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.